SCHEMBL24130429

SCHEMBL24130429

Cn1c(=O)n(-c2ccccc2)c2cc(NN=C(C#N)C#N)cnc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ MEN1 O00255 3/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ GAA P10253 2/20 0.45
▸ GSK3B P49841 3/20 0.42
▸ TDP1 Q9NUW8 3/20 0.41
▸ NPSR1 Q6W5P4 2/20 0.41
▸ HSD17B10 Q99714 3/20 0.36
▸ CYP3A4 P08684 2/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ CISD1 Q9NZ45 1/20 0.36
▸ PRKDC P78527 2/20 0.36
▸ PIK3CA P42336 2/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26280685 0.86 GSK3B (0.45) MAPTALDH1A1KMT2ASMN1; SMN2GAA
SCHEMBL24130525 0.86 HTT (0.46) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL24130498 0.81 MAPT (0.38) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL24130499 0.81 ALDH1A1 (0.38) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL24130149 0.80 MAPT (0.37) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL24130682 0.76 MAPT (0.37) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL24130532 0.76 MAPT (0.37) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL24130496 0.74 PRKDC (0.41) MAPTALDH1A1TDP1NPSR1PRKDC
SCHEMBL24130531 0.73 MAPT (0.39) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL25407446 0.71 MAPK1 (0.48) ALDH1A1SMN1; SMN2GSK3BHSD17B10PRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295095-A1 NOVEL FUSED-HETEROCYCLYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS AND USE THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2023-09-21 — — US disclosed
US-20230295095-A1 NOVEL FUSED-HETEROCYCLYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS AND USE THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2023-09-21 — — US disclosed
EP-4169905-A1 NOVEL FUSED HETEROCYCLIC CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF Korea Institute of Science and Technology (KR) 2023-04-26 — — EP disclosed
WO-2021256899-A1 NOVEL FUSED HETEROCYCLIC CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF 한국과학기술연구원 2021-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295095-A1 NOVEL FUSED-HETEROCYCLYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS AND USE THEREOF CBR3, DBF4, DDT MAPT 3518/4885ALDH1A1 1343/4885MEN1 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback